Your session is about to expire
← Back to Search
Nivolumab + Ipilimumab for Prostate Cancer (CheckMate 650 Trial)
CheckMate 650 Trial Summary
This trial will test a new cancer treatment involving two drugs, to see if it is effective, safe, and tolerable for patients with mCRPC.
CheckMate 650 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCheckMate 650 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533CheckMate 650 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or can carry out light work.I was previously in Arm D3 or D4 of the trial, have prostate cancer confirmed by tests, and it's stage IV.I have been treated with specific immune system targeting drugs before.I have received cancer treatment after my last dose of the study medication.I have an autoimmune disease or a current infection.I had radiation therapy within the last 14 days before starting nivolumab with ipilimumab.My scans show cancer has spread to my bones or soft tissues.My cancer has spread to my liver.I am on hormone therapy for cancer and my testosterone is very low.I have active brain or spinal cord cancer spread.
- Group 1: Cohort D (Arm D4)
- Group 2: Cohort D (Arm D3)
- Group 3: Cohort C (Arm C)
- Group 4: Cohort D (Arm D1)
- Group 5: Cohort A (Arm A)
- Group 6: Cohort D (Arm D2)
- Group 7: Cohort B (Arm B)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people can enroll in this research project?
"Although this study is not recruiting at the moment, it was last updated on November 15th, 2022. There are presently 1366 clinical trials actively recruiting patients with prostate cancer and 1142 trials for Nivolumab actively recruiting patients."
In how many distinct places is this research being conducted?
"There are 37 sites running this clinical trial, including Local Institution - 0074 in Tucson, Arizona, Comprehensive Cancer Center Of Nevada in Las Vegas, Nevada and Minnesota Oncology Hematology (Minneapolis) - USOR in Minneapolis, Minnesota."
Could you please list other research that has been published on Nivolumab?
"There are currently 1142 ongoing Nivolumab trials worldwide, with 178 of them in Phase 3. Though the majority of these studies originate from Pittsburgh, PA, there are 58497 locations conducting research for this medication."
Are there any empty slots in this experiment that individuals could participate in?
"Currently, this clinical trial is not enrolling patients. Although, it was first posted on March 26th 2017 and last edited on November 15th 2022. There are 1,366 other trials for prostate cancer and 1142 for Nivolumab that are currently looking for participants."
What are the government's thoughts on Nivolumab?
"Nivolumab's safety is based on data from Phase 2 trials, meaning that while there is evidence of its safety, there is currently no clinical data to support efficacy."
For what reasons is Nivolumab generally prescribed?
"Nivolumab can be used as an immunotherapy treatment for patients with unresectable melanoma, squamous cell carcinoma, and ulcerative colitis."
Share this study with friends
Copy Link
Messenger